10.67 USD
-0.02 (-0.19%)
Overall EVOK gets a fundamental rating of 3 out of 10. We evaluated EVOK against 192 industry peers in the Pharmaceuticals industry. EVOK has a bad profitability rating. Also its financial health evaluation is rather negative. EVOK is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
EVOK had negative earnings in the past year.
In the past year EVOK has reported a negative cash flow from operations.
EVOK had negative earnings in each of the past 5 years.
EVOK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
EVOK has a Return On Assets (-33.51%) which is in line with its industry peers.
EVOK has a Return On Equity of -123.04%. This is in the lower half of the industry: EVOK underperforms 65.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.51% | ||
| ROE | -123.04% | ||
| ROIC | N/A |
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EVOK has a Gross Margin of 96.63%. This is amongst the best in the industry. EVOK outperforms 96.88% of its industry peers.
EVOK's Gross Margin has improved in the last couple of years.
EVOK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, EVOK has more shares outstanding
EVOK has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, EVOK has an improved debt to assets ratio.
2.2 Solvency
EVOK has an Altman-Z score of -10.60. This is a bad value and indicates that EVOK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -10.60, EVOK is not doing good in the industry: 71.88% of the companies in the same industry are doing better.
EVOK has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
EVOK has a Debt to Equity ratio of 1.14. This is in the lower half of the industry: EVOK underperforms 73.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.6 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.37 indicates that EVOK should not have too much problems paying its short term obligations.
With a Current ratio value of 1.37, EVOK is not doing good in the industry: 72.40% of the companies in the same industry are doing better.
EVOK has a Quick Ratio of 1.32. This is a normal value and indicates that EVOK is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of EVOK (1.32) is worse than 69.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.32 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 79.89% over the past year.
The Revenue has grown by 97.84% in the past year. This is a very strong growth!
The Revenue has been growing by 84.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)79.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.13%
Revenue 1Y (TTM)97.84%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%61.42%
3.2 Future
Based on estimates for the next years, EVOK will show a very strong growth in Earnings Per Share. The EPS will grow by 34.84% on average per year.
Based on estimates for the next years, EVOK will show a very strong growth in Revenue. The Revenue will grow by 52.59% on average per year.
EPS Next Y55.96%
EPS Next 2Y46.42%
EPS Next 3Y34.84%
EPS Next 5YN/A
Revenue Next Year57.78%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
EVOK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
EVOK is valuated correctly with a Price/Forward Earnings ratio of 16.34.
Based on the Price/Forward Earnings ratio, EVOK is valued cheaper than 80.73% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, EVOK is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 16.34 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EVOK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EVOK's earnings are expected to grow with 34.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.42%
EPS Next 3Y34.84%
5. Dividend
5.1 Amount
EVOK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:EVOK (11/21/2025, 8:25:42 PM)
10.67
-0.02 (-0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners26%
Inst Owner Change154.59%
Ins Owners1.13%
Ins Owner Change0%
Market Cap16.65M
Revenue(TTM)10.25M
Net Income(TTM)-5.38M
Analysts82.86
Price Target18.36 (72.07%)
Short Float %0.55%
Short Ratio0.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-77.06%
Min EPS beat(2)-102.61%
Max EPS beat(2)-51.52%
EPS beat(4)1
Avg EPS beat(4)-73.67%
Min EPS beat(4)-142.52%
Max EPS beat(4)1.96%
EPS beat(8)3
Avg EPS beat(8)-37.13%
EPS beat(12)6
Avg EPS beat(12)-22.72%
EPS beat(16)8
Avg EPS beat(16)-19.86%
Revenue beat(2)0
Avg Revenue beat(2)-6.01%
Min Revenue beat(2)-8.93%
Max Revenue beat(2)-3.1%
Revenue beat(4)1
Avg Revenue beat(4)-7.34%
Min Revenue beat(4)-22.51%
Max Revenue beat(4)5.18%
Revenue beat(8)3
Avg Revenue beat(8)-5.48%
Revenue beat(12)5
Avg Revenue beat(12)-2.75%
Revenue beat(16)6
Avg Revenue beat(16)1.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 16.34 | ||
| P/S | 1.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.81 | ||
| P/tB | 3.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.21
EYN/A
EPS(NY)0.65
Fwd EY6.12%
FCF(TTM)-2.32
FCFYN/A
OCF(TTM)-2.32
OCFYN/A
SpS8.2
BVpS2.8
TBVpS2.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.51% | ||
| ROE | -123.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.63% | ||
| FCFM | N/A |
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
F-Score5
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.32 | ||
| Altman-Z | -10.6 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.13%
EPS Next Y55.96%
EPS Next 2Y46.42%
EPS Next 3Y34.84%
EPS Next 5YN/A
Revenue 1Y (TTM)97.84%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%61.42%
Revenue Next Year57.78%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A
EBIT growth 1Y14.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.86%
OCF growth 3YN/A
OCF growth 5YN/A
EVOKE PHARMA INC / EVOK FAQ
Can you provide the ChartMill fundamental rating for EVOKE PHARMA INC?
ChartMill assigns a fundamental rating of 3 / 10 to EVOK.
What is the valuation status of EVOKE PHARMA INC (EVOK) stock?
ChartMill assigns a valuation rating of 4 / 10 to EVOKE PHARMA INC (EVOK). This can be considered as Fairly Valued.
Can you provide the profitability details for EVOKE PHARMA INC?
EVOKE PHARMA INC (EVOK) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for EVOK stock?
The Earnings per Share (EPS) of EVOKE PHARMA INC (EVOK) is expected to grow by 55.96% in the next year.